Response rates of FAS in this study. Response rates of all 9 patients of FAS at each treatment point. The CR rate at week 8 or at the time of early termination (the primary end point) was 2 of 9 (22.2%; 95% CI, 2.8-60.0; the middle bar. ∗NE owing to short-term administration (<4 weeks); ∗∗NE owing to ruxolitinib discontinuation before evaluation. NE, not evaluable.